Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06321536 · ClinicalTrials.gov registry record · Phase 2
Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)
A Phase 2 study of Multi-Drug Resistant Organism Colonization, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT06321536: Recruiting Phase 2 study of Multi-Drug Resistant Organism Colonization, sponsored by Emory University.
NCT06321536 is a Phase 2 study of Multi-Drug Resistant Organism Colonization that is actively recruiting participants, run by Emory University. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06321536, a Phase 2 study of Multi-Drug Resistant Organism Colonization, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.
Primary Outcome
Difference in number of solicited AEs between Day 0 and Day 7 in AMG-treated vs Observation participants.
Conditions Studied
Interventions
- DRUG Allogeneic Microbiota in Glycerol (9%) (AMG)
Study Locations (4)
Georgia
- A.G Rhodes Wesley Woods - Atlanta
- Emory Long Term Acute Care (LTAC) - Decatur
Illinois
- RML Specialty Hospital - Hinsdale
Pennsylvania
- Penn Medicine Rittenhouse - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT06321536 shows while recruiting
NCT06321536 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Multi-Drug Resistant Organism Colonization appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic Microbiota in Glycerol (9%) (AMG) is the first listed.
NCT06321536 reports a single indexed study location in Georgia, Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06321536 about?
NCT06321536 is a clinical study titled "Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)". REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT...
What is the current status of trial NCT06321536?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-01-13. Estimated completion is 2026-12.
What conditions does trial NCT06321536 study?
This clinical trial studies the following conditions: Multi-Drug Resistant Organism Colonization.
What interventions are being tested in trial NCT06321536?
The interventions under investigation include: Allogeneic Microbiota in Glycerol (9%) (AMG) (DRUG).
Who is sponsoring clinical trial NCT06321536?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06321536 being conducted?
This trial has 4 study locations across Georgia, Illinois, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06321536's enrollment target sits among peer trials
60 1027th of 2000 higher than 869 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI